EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria

Katrine Baumann iD, Astrid-Helene Ravn Jørgensen, Jennifer Astrup Sørensen, Ditte Georgina Zhang iD, Misbah Noshela Ghazanfar iD, Per Stahl Skov, Anders Woetmann, Christian Vestergaard, Marcus Maurer iD, Simon Francis Thomsen

Clinical & Experimental Allergy · 2023

DOI: 10.1111/cea.14402 ↗

At a glance

Journal article in Clinical & Experimental Allergy, 2023. Written by Katrine Baumann and 9 co-authors. Institution: Urticaria Center of Reference and Excellence (UCARE), Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denm…. Major MEDLINE topics: Chronic Urticaria, Anti-Allergic Agents, Urticaria. Cited 11 times so far (Crossref); 9 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Novo Nordisk Fonden.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Intet abstract tilgængeligt.

Subjects

MeSH terms (MEDLINE)

Chronic UrticariaAnti-Allergic AgentsUrticariaHumansOmalizumabBasophilsHistamine ReleaseChronic Disease

Substances

OmalizumabAnti-Allergic Agents

Authors and institutions

  • Urticaria Center of Reference and Excellence (UCARE), Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark.
  • RefLab ApS, Copenhagen, Denmark.
  • LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
  • Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Venerology, Aarhus University Hospital, Aarhus, Denmark.
  • Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.

ORCID profiles: Katrine Baumann, Ditte Georgina Zhang, Misbah Noshela Ghazanfar, Marcus Maurer

Funding

  • Novo Nordisk Fonden

Cite

APA

Baumann, K., Jørgensen, A. R., Sørensen, J. A., Zhang, D. G., Ghazanfar, M. N., Skov, P. S., Woetmann, A., Vestergaard, C., Maurer, M., & Thomsen, S. F. (2023). Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14402

Vancouver

Baumann K, Jørgensen AR, Sørensen JA, Zhang DG, Ghazanfar MN, Skov PS, et al. Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria. Clinical & Experimental Allergy. 2023. doi:10.1111/cea.14402

BibTeX
@article{Baumann2023,
  author = {Baumann, Katrine and Jørgensen, Astrid-Helene Ravn and Sørensen, Jennifer Astrup and Zhang, Ditte Georgina and Ghazanfar, Misbah Noshela and Skov, Per Stahl and Woetmann, Anders and Vestergaard, Christian and Maurer, Marcus and Thomsen, Simon Francis},
  title = {Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria},
  journal = {Clinical & Experimental Allergy},
  year = {2023},
  doi = {10.1111/cea.14402}
}
Start for free →